EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Emergent BioSolutions Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCM Products | $168.00M | $101.80M | $99.20M | $142.50M | $58.40M | $156.60M | $116.80M | $174.20M | $63.40M | $155.40M | $138.00M | $107.70M | 71.7% | +187.7% |
| Commercial Products | $52.40M | $42.90M | $38.40M | $74.90M | $67.50M | $45.30M | $65.10M | $95.30M | $120.00M | $118.50M | $111.10M | $142.10M | 22.4% | -22.4% |
| Products | – | – | – | – | – | – | – | – | – | – | – | $249.80M | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and services sales, net | $226.80M | $149.70M | $143.80M | $222.00M | $130.30M | $209.10M | $189.30M | $283.80M | $248.10M | $292.40M | – | – | 96.8% | +74.1% |
| MCM Product sales | $168.00M | $101.80M | $99.20M | $142.50M | $58.40M | $156.60M | $116.80M | $174.20M | $63.40M | $155.40M | $138.00M | $107.70M | 71.7% | +187.7% |
| Commercial Product sales | $52.40M | $42.90M | $38.40M | $74.90M | $67.50M | $45.30M | $65.10M | $95.30M | $120.00M | $118.50M | $111.10M | $142.10M | 22.4% | -22.4% |
| All other revenue | $13.90M | $11.40M | $11.10M | $13.70M | $15.00M | $20.30M | $12.80M | $24.30M | $71.30M | $26.50M | – | – | 5.9% | -7.3% |
| Contracts and grants | $7.50M | $6.40M | $4.90M | $9.10M | $10.60M | $13.10M | $5.40M | $10.00M | $6.60M | $8.00M | $6.70M | $6.50M | 3.2% | -29.2% |
| Products | – | – | – | – | – | – | $181.90M | $269.50M | $183.40M | $273.90M | $249.10M | $249.80M | – | – |
| Service | – | – | – | – | – | – | $6.80M | $13.90M | $64.50M | $18.30M | $20.60M | $13.20M | – | – |
By region
From the segment and revenue-disaggregation notes of Emergent BioSolutions's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.